Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
Preserved GlobalRPh source, not a freshly verified product label
Renal measure
Use the method specified in the original source
Source revision
Historical source; revision not established here
Retrieved
2026-09-05 (not the revision date)
Historical source: not automatically current. Review current official labeling and separately attributed additions before use.
Clinical pharmacology
Beta-adrenergic blocker: preferential beta1 selectivity in extensive metabolizers at doses up to 10 mg; both beta1 and beta2 inhibition in poor metabolizers or at higher doses. No intrinsic sympathomimetic or membrane-stabilizing activity at therapeutic concentrations and no clinically relevant alpha1 blockade. Metabolites, including glucuronides, contribute to beta blockade.
Usual Dosing (Adults)
Hypertension, alone or in combination: usually start 5 mg once daily with or without food. Individualize and increase at 2-week intervals to 40 mg if further blood-pressure lowering is required. More frequent dosing is unlikely to help.
Renal Dosing
Severe impairment, CrCl below 30 mL/min: start 2.5 mg once daily and titrate slowly as needed.
Hemodialysis
Not studied in dialysis patients in the source.
Source revision: Historical source; revision not established here | Retrieved: 2026-09-05. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Bystolic - product and source limitations
Dialysis patients were not studied. Follow blood pressure and heart rate during titration.
How to use this: Apply only to the stated formulation, indication and renal population.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Bystolic - labeled renal guidance
Nebivolol (Bystolic), adult oral tablets for hypertension
Method: Creatinine clearance (CrCl), mL/min; use the product-specific calculation
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content
Original GlobalRPh protocol
Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/nebivolol/
Clinical pharmacology
Beta-adrenergic blocker: preferential beta1 selectivity in extensive metabolizers at doses up to 10 mg; both beta1 and beta2 inhibition in poor metabolizers or at higher doses. No intrinsic sympathomimetic or membrane-stabilizing activity at therapeutic concentrations and no clinically relevant alpha1 blockade. Metabolites, including glucuronides, contribute to beta blockade.
Hypertension, alone or in combination: usually start 5 mg once daily with or without food. Individualize and increase at 2-week intervals to 40 mg if further blood-pressure lowering is required. More frequent dosing is unlikely to help.
Renal guidance: 2.1 and 5, impaired renal function
Start at 2.5 mg once daily when CrCl is below 30 mL/min. Titrate slowly as needed. Dialysis patients were not studied. Follow blood pressure and heart rate during titration.
RDM73-bystolic-tablets-official-1 · Source locator: Renal guidance: 2.1 and 5, impaired renal function
GlobalRPh RX List / product-label mirror · Nebivolol (Bystolic), adult oral tablets for hypertension
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.
